Jacobs & Co. CA Has $1.20 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Jacobs & Co. CA decreased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 17.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,338 shares of the medical equipment provider’s stock after selling 2,429 shares during the quarter. Jacobs & Co. CA’s holdings in Zimmer Biomet were worth $1,197,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC raised its stake in shares of Zimmer Biomet by 8.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 15,845 shares of the medical equipment provider’s stock valued at $1,710,000 after buying an additional 1,173 shares in the last quarter. ORG Partners LLC increased its position in shares of Zimmer Biomet by 14,497.5% during the 4th quarter. ORG Partners LLC now owns 5,839 shares of the medical equipment provider’s stock worth $617,000 after purchasing an additional 5,799 shares in the last quarter. First Hawaiian Bank increased its position in shares of Zimmer Biomet by 14.0% during the 4th quarter. First Hawaiian Bank now owns 20,400 shares of the medical equipment provider’s stock worth $2,155,000 after purchasing an additional 2,500 shares in the last quarter. Nordea Investment Management AB increased its position in shares of Zimmer Biomet by 3.9% during the 4th quarter. Nordea Investment Management AB now owns 16,333 shares of the medical equipment provider’s stock worth $1,732,000 after purchasing an additional 609 shares in the last quarter. Finally, Central Pacific Bank Trust Division increased its position in Zimmer Biomet by 7.4% in the 4th quarter. Central Pacific Bank Trust Division now owns 14,525 shares of the medical equipment provider’s stock valued at $1,534,000 after acquiring an additional 1,000 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 2.4 %

ZBH stock traded up $2.41 during mid-day trading on Friday, hitting $103.95. 1,517,551 shares of the company were exchanged, compared to its average volume of 1,565,623. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The firm has a market cap of $20.69 billion, a P/E ratio of 19.76, a P/E/G ratio of 1.96 and a beta of 1.02. The firm’s 50 day simple moving average is $108.09 and its 200 day simple moving average is $108.05. Zimmer Biomet Holdings, Inc. has a 1-year low of $100.67 and a 1-year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same period last year, the company posted $1.65 EPS. The business’s quarterly revenue was up 4.1% on a year-over-year basis. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 18.25%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Barclays lowered their price objective on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a research report on Thursday, December 12th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Wells Fargo & Company raised their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Raymond James reduced their target price on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. Finally, Truist Financial raised their target price on shares of Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $123.33.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.